Q-omics provides the consensus-scored NDUFB11 profile across patient tissues and cancer cell-line models. NDUFB11 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NDUFB11 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, NDUFB11 protein abundance shows 24,697 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, COAD, and GBM as cancer lineages where NDUFB11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFB11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFB11 survival associations across molecular data types. NDUFB11 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFB11 RNA expression–survival associations across cancer types. High NDUFB11 expression shows unfavorable associations in KICH, LUAD, UCS, KIRP and LIHC, but favorable associations in OV. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify KICH as the clearest survival context for NDUFB11 RNA expression.
This table summarizes NDUFB11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFB11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFB11 shows higher tumor expression in COAD, LIHC, LUAD, BRCA, UCEC and BLCA. The COAD box plot shows higher NDUFB11 RNA expression in tumor versus normal tissue (log2 FC = +0.621, t-test p < 0.001).
This table shows molecular features associated with NDUFB11 in patient tissues and cancer cell lines. In patient samples, NDUFB11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFB11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
